Addressing Unmet Needs in Heart Failure with Preserved Ejection Fraction: Multi-Omics Approaches to Therapeutic Discovery
International Journal of Molecular Sciences · 09.01.2026 · 27 (2) · 673
DOI: 10.3390/ijms27020673 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.01.2026. Verfasst von Taemin Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Warren Alpert Medical School, Brown University, Providence, RI 02903, USA. Hauptthemen laut MEDLINE: Heart Failure, Stroke Volume. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Heart failure with preserved ejection fraction (HFpEF) accounts for about half of heart failure cases and is linked to aging, obesity, diabetes, and multimorbidity, yet disease-modifying therapies remain limited. A major barrier is heterogeneity: HFpEF comprises overlapping inflammatory, fibrotic, cardiometabolic, and hemodynamic/vascular endophenotypes embedded within systemic cardiorenal and cardiohepatic cross-talk, which conventional metrics such as left ventricular ejection fraction (LVEF), natriuretic peptides (NPs), and standard imaging capture incompletely. In this narrative review, we synthesize clinical, mechanistic, and trial data to describe HFpEF endophenotypes and their multi-organ interactions; critically appraise why traditional diagnostic and enrollment strategies contributed to neutral outcomes in landmark trials; and survey emerging cardiovascular multi-omics studies. We then outline an integrative systems-biology framework that applies (i) within-layer analyses and cross-layer integration, (ii) network-based driver nomination and biomarker discovery, and (iii) target nomination to link molecular programs with circulating markers and candidate therapies. Finally, we discuss practical challenges in implementing multi-omics HFpEF research and highlight future directions such as artificial intelligence (AI)-enabled multi-omics integration, cross-organ profiling, and biomarker-guided, endotype-enriched platform trials. Collectively, these advances position HFpEF as a proving ground for precision cardiology, in which therapies are matched to molecularly defined disease programs rather than ejection-fraction cutoffs alone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Warren Alpert Medical School, Brown University, Providence, RI 02903, USA.
- Cardiology Section, VA Providence Healthcare System, Providence, RI 02908, USA.
ORCID-Profile: Taemin Kim, Michael Sheen
Zitieren
APA
Kim, T., Sheen, M., Ryan, D., & Joseph, J. (2026). Addressing Unmet Needs in Heart Failure with Preserved Ejection Fraction: Multi-Omics Approaches to Therapeutic Discovery. International Journal of Molecular Sciences, 27(2), 673. https://doi.org/10.3390/ijms27020673
Vancouver
Kim T, Sheen M, Ryan D, Joseph J. Addressing Unmet Needs in Heart Failure with Preserved Ejection Fraction: Multi-Omics Approaches to Therapeutic Discovery. International Journal of Molecular Sciences. 2026;27(2):673. doi:10.3390/ijms27020673
BibTeX
@article{Kim2026,
author = {Kim, Taemin and Sheen, Michael and Ryan, Daniel and Joseph, Jacob},
title = {Addressing Unmet Needs in Heart Failure with Preserved Ejection Fraction: Multi-Omics Approaches to Therapeutic Discovery},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {2},
pages = {673},
doi = {10.3390/ijms27020673}
}
EUVIMED